Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy

There have been few reports on 2 tumor necrosis factor alpha inhibitors, infliximab and adalimumab, with respect to patient preference and efficacy in ulcerative colitis (UC). We used questionnaires to evaluate the preference and reasons for drug choice between infliximab and adalimumab in UC patien...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Medicine (Baltimore)
Asıl Yazarlar: Mizoshita, Tsutomu, Katano, Takahito, Tanida, Satoshi, Hirano, Atsuyuki, Miyaki, Tomokatsu, Ozeki, Keiji, Suzuki, Yuka, Sugimura, Naomi, Kataoka, Hiromi, Joh, Takashi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wolters Kluwer Health 2017
Konular:
4500
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5556246/
https://ncbi.nlm.nih.gov/pubmed/28796080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000007800
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller